Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer
This is a retrospective genetic analysis of stored tumor tissue samples to evaluate the distribution of Recurrence Score® and gene groups of stage II colon cancer in African American (AA) and Caucasian individuals. Other covariant factors in the medical chart will be analyzed as well. Three institutions will contribute patients to this study with a total patient number goal of approximately 200 with approximately 100 being AA and approximately 100 being Caucasian. As enrollment in this study proceeds a Caucasian subject will be matched for every African American enrolled.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
- Compare the prognosis of colon cancer patients compared to gene expression. [ Time Frame: 1 year ] [ Designated as safety issue: No ]Compare the values of the Recurrence Score and expression levels of gene groups and individual genes between African Americans and Caucasians with Stage II colon cancer
Biospecimen Retention: Samples With DNA
The Oncotype DX Colon Cancer Assay will be utilized to define the gene expression profile of the tumor tissue.
|Study Start Date:||November 2011|
|Study Completion Date:||January 2015|
|Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01479894
|United States, Arkansas|
|University of Arkansas for Medical Sciences|
|Little Rock, Arkansas, United States, 72120|